Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 6, 2002, Pages 2784-2791

  Miyazaki, Yoshinori ^a   Mahankali, Archana ^a   Matsuda, Masafumi ^a   Mahankali, Srikanth ^a   Hardies, Jean ^a   Cusi, Kenneth ^a   Mandarino, Lawrence J ^a   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE;

ADULT; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

EID: 0036072223     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.6.8567     Document Type: Article

References (46)

1. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
2. Effects of troglitazone: A new hypoglycemic agent in patient with NIDDM poorly controlled by diet therapy
3. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus; a randomized, double-blind, placebo-controlled trial
4. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
5. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes
6. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
7. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
8. Pioglitazone induces in vivo adipocyte differentiation in obese Zucker fa/fa rats
9. A human peroxisome-proliferator-activated receptor γ is activated by inducers of adipogenesis, including thiazolidinedione drugs
10. Effects of troglitazone on body fat distribution in type 2 diabetic patients
11. Rosiglitazone monotherapy improve glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study
12. Long-term effects of troglitazone: Open-label extension studies in type 2 diabetic patients
13. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
14. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM
15. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease
16. Regional adiposity and morbidity
17. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
18. Measurement of abdominal fat with T1-weighted MR images
19. Glucose clamp technique: A method for quantifying insulin secretion and resistance
20. Indirect calorimetry: Methodological and interpretative problems
21. Influence of glucose loading and of injected insulin on hepatic glucose output
22. Relationship between total body water and surface area in normal and obese subjects
23. Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting
24. Peroxisome proliferator-activated receptor gene expression in human tissues: Effects of obesity, weight loss and regulation by insulin and glucocorticoids
25. Troglitazone increase the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
26. Depot-specific differences in adipose tissue gene expression in lean and obese subjects
27. PPARγ, the ultimate thrifty gene
28. Surgical removal of visceral fat reverses hepatic insulin resistance
29. Differences in lipolysis between human subcutaneous and omental adipose tissues
30. Control mechanisms of gluconeogenesis and ketogenesis
31. The effect of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects
32. In vitro studies on the action of CS-045, a new antidiabetic agent
33. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: Contribution of excessive hepatic glucose production and impaired tissue glucose uptake
34. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM
35. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
36. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects
37. IRS-1-mediated inhibition receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance
38. Leptin selectively decreases visceral adiposity and enhances peripheral and hepatic insulin action
39. Severely impaired adipsin expression in genetic and acquired obesity
40. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease
41. The hormone resistin links obesity to diabetes
42. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials
43. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus
44. The disposal of an oral glucose load in healthy subjects. A quantitative study
45. Role of fractional glucose extraction in the regulation of splanchnic glucose metabohsm in normal and diabetic man
46. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp